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Background: Amlodipine, a dihydropyridine calcium channel blocker (CCB) is commonly prescribed for cardio-
vascular conditions. Its administration may produce an uncommon adverse oral manifestation, the gingival over-
growth (GO). Lately, there has been an increase in the rate of GO in patients on amlodipine therapy. The current 
systematic review was undertaken to evaluate the evidence on plausible risk factors involved in amlodipine induced 
gingival overgrowth (AIGO).
Material and Methods: Literature search was conducted in the databases like Pubmed (Medline), Scopus and Goo-
gle Scholar to include the original research articles related to etio-pathogenesis of AIGO. 
Results: About 270 documents were identified through primary search, of which 13 original research articles were 
included. Most common risk factor for AIGO was administration of amlodipine in subjects with poor plaque con-
trol. However, high dosage of drug, duration of therapy and inherent genetic susceptibility were recognized as other 
plausible risk factors. 
Conclusions: It was concluded that AIGO is no longer a rare phenomenon. It is therefore imperative for the physi-
cian to identify and inform patients, about the risk factors associated with the overgrowth at the initiation of therapy. 
This would prevent the development of GO’s and improve the patient’s quality of life. 
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Introduction
Hypertension, a “silent killer” is one of the most im-
portant modifiable risk factors for cardiovascular and 
associated conditions like stroke, dementia, ischemic 
heart disease, vision loss, heart and kidney failures (1). 
About one billion adults are hypertensive globally and 
this number may reach 1.56 billion by the year 2025, 
a sharp increase of about 60% from the year 2000 (2). 
The increasing prevalence of hypertension has been at-
tributed to population overgrowth, ageing, behavioral 
and lifestyle associated risk factors. About 9.4 million 
people die every year because of hypertension and its 
complications and half of them are related to heart di-
sease and stroke (3).
For decades, antihypertensive drugs including diuretics, 
alpha and beta blockers, angiotensin converting enzyme 
(ACE) inhibitors, angiotensin II type 1 receptor blockers 
(ARB) and calcium channel blockers (CCB’s) have been 
used to manage these conditions (1). They are adminis-
tered either alone or in combination, depending on the 
needs of the patient. 
The CCB’s are the most common antihypertensive 
agents, prescribed in about 37% of the cases. They com-
prise of two subclasses, dihydropyridines and non-dihy-
dropyridines (2). Although their mechanism of action 
is the same, they have varied pharmacological effects. 
While the dihydropyridines are potent vasodilators, the 
non-dihydropyridines produce more negative intropic 
effects. The former were first introduced in 1960’s. Sin-
ce then they have undergone several modifications to 
improve their efficacy and safety resulting in their four 
generations. The first-generation (e.g. nicardipine and 
nifedipine) were very effective but owing to their short 
duration and rapid vasodilator action, they produced 
more adverse effects. This was followed by the develo-
pment of second (e.g. benidipine, and efonidipine), third 
(e.g. amlodipine and azelnidipine) and fourth (e.g. lerca-
nidipine and lacidipine) generation agents which were 
relatively stable with less side effects. 
Amongst the CCB’s, amlodipine, a third generation 
agent, is prescribed very frequently. It may be used ei-
ther alone or in combination therapy. These medications 
often require lifelong administration, exposing the pa-
tients to side effects including adverse oral reactions like 
gingival overgrowths (GO). 
In general, GO may be inflammatory (as a consequen-
ce of accumulation of bacterial dental plaque), idiopa-
thic, related to systemic conditions like scurvy, leuke-
mia, neoplasia, hormonal imbalances (e.g. puberty and 
pregnancy) or administration of medications. Currently, 
more than 20 prescription medications are associated 
with gingival enlargement. These include anticonvul-
sants (e.g. phenytoin), immunosuppressants (e.g. cy-
closporine A) and CCB’s like nifedipine, diltiazem and 
verapamil (4). The prevalence of CCB induced GO was 
about 6-15% for nifedipine, 5-20% for diltiazem and 
5% for verapamil (4). They were rarely seen with amlo-
dipine and felodipine usage, until 1993, when the first 
case of amlodipine induced GO (AIGO) was reported 
(5). It has been suggested that age, genetics, drug varia-
bles and pre-existing gingival inflammation all influence 
the response of gingiva to these medications (6). They 
produce massive enlargements which may be localized 
or generalized. These subsequently interfere with routi-
ne oral hygiene practices and promote bacterial plaque 
accumulation and inflammation. Thus a vicious cycle 
is developed resulting in persistent overgrowths that 
complicate the masticatory function and esthetics. In 
the past, various mechanisms like disturbed fibroblastic 
proliferation and apoptosis as well as altered connective 
tissue hemostasis were implied in the pathogenesis of 
drug induced GO (DIGO) (Fig. 1).
Fig. 1: Mechanism of amlodipine induced gingival overgrowth.
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Lately, there has been a rise in the number of reports 
related to GO in amlodipine treated cases (7). Althou-
gh various mechanisms have been proposed, the exact 
role of amlodipine in GO is yet to be elucidated. With 
this background the current review aims to evaluate the 
evidence on plausible risk factors for this alleged rare 
occurrence.
Material and Methods
The research question was formulated using the guide-
lines of Preferred Reporting Items for Systematic Re-
views and Meta-Analysis (PRISMA) and according to 
the Participants, Interventions, Control, and Outcomes 
(PICO) principle. 
a. Focused Question
The focused questions of interest was “Is dental plaque 
the only etiological factor in Amlodipine induced gingi-
val overgrowth?”
b. Eligibility Criteria
Our search included longitudinal, case-control and 
cross-sectional studies to identify the various plausible 
risk factors for AIGO. Only free full text articles of these 
studies were included if they identified risk factors rela-
ted to etiopathogensis of AIGO.
Exclusion criteria were animal studies, experimental stu-
dies, in vitro studies, reviews, case reports/series or stu-
dies involving pediatric patients, conference papers and 
documents published in a language other than English.
c. Literature Search strategy
Literature search was made to include the longitudinal, 
case-control and cross-sectional studies on AIGO. A sys-
tematic search of the electronic databases PubMed (Med-
line), Scopus and Google Scholar was performed from 
2013 to January 2018 using a combination of keywords 
like Amlodipine, Gingiva, Gingival, Overgrowth, Enlar-
gement and Hyperplasia. These terms were searched in 
title, abstracts or keywords. The titles and abstracts of re-
trieved studies were screened for eligibility by the authors 
and all irrelevant studies were excluded. The full texts of 
the articles were then read and assessed for inclusion.
d. Data extraction
The following data were extracted from the included ar-
ticles by two independent authors using a standardized 
data collection form: authors and year of study, study 
design, number of subjects, mean age, drug variables 
(mean dosage, duration and frequency of amlodipine 
usage), periodontal variables (degree of GO, plaque in-
dex and gingival index) and the main outcomes.
Disagreements were resolved by discussion between the 
authors and a consensus was reached before including 
the studies in the review. 
e. Assessment of quality
The critical appraisal of the included studies was per-
formed using the criteria from Strengthening the Re-
porting of Observational studies in Epidemiology Sta-
tement (STROBE) (8). Following eight criteria were 
considered most important in the context of this review 
and were included in the checklist: reporting of study 
design, description of study participants, justification of 
sample size, inclusion of drug and periodontal variables, 
potential confounders, measurement of the outcomes 
and appropriate statistical analysis. Each criterion was 
given a response of either “Yes” or “NO”. Each study 
could have a maximum score of 8. After the scores were 
summed, the methodological quality was graded as low 
(0-3), acceptable (4-6), and high (7-8).
Results
a. Study selection
The search strategy for identification of relevant studies 
following the PRISMA guidelines is presented in Figure 
2. An initial search identified a total of 270 documents. 
Of these 67 documents were removed due to overlap-
ping. Further screening of 203 documents resulted in 27 
original research. Among them 7 documents were ex-
cluded due to non-availability of free full text. The full 
texts of 20 documents were studied in detail. Of these, 
7 were excluded as they were either experimental or in 
vitro studies or lacked relevant information. Finally, 13 
original research articles were included in the systematic 
review and processed for data extraction. 
b. Characteristics of the original studies
The characteristics of the original research studies have 
been summarized in table 1, 1 continue, 1 continue-1. 
There were 10 cross- sectional (7,9-12,14,16,18-20) and 
3 case control studies (13,15,17). About 7 studies were 
conducted in India (7,13-17,19) and one each in Uni-
ted States of America (9), United Kingdom (10), Japan 
(11), Germany (12), Sudan (18) and Nigeria (20). The 
total number of subjects involved in these studies ran-
ged from 25 to 4290 with the number of males having 
AIGO being more than females. Some studies involved 
estimation of prevalence of amlodipine intake in patients 
on CCB’s and further evaluated the presence of GO 
(7,10,12,20). The mean age of the subjects on amlodipi-
ne therapy ranged between 30 to 87 years. 
c. Clinical Periodontal Parameters estimated
The plaque and other triggering factors for AIGO 
were measured with the help of Plaque index (7,9,13-
15,17,20), Calculus index (12,16) and simplified oral 
hygiene index (13,18) in the included studies. The pe-
riodontal status was evaluated by measuring Gingival 
Index (7,13-15,17,20), Probing pocket depths (7,12,16) 
and Clinical attachment loss (12,16). Furthermore, diffe-
rent GO indices were utilized to measure the horizontal 
and vertical component of GO (7,9,10,13-20). Additio-
nally, the expression of Bcl2 gene was observed in the 
histological samples of overgrown gingival tissues in 
one study (15). Other confounding factors like smoking 
were assessed in two studies (7,12).
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Fig. 2: Search strategy for Original research articles.
 
Author  Location Type of Study Aim of the Study Salient Features of the study Results and Conclusion 
Jorgensen, M.G, 1997 
(9) 
USA Cross -sectional 
study 
Examined a large group of 
patients on amlodipine to 
determine the prevalence of GO 
150 dentate patients on amlodipine (5 mg/day) for at least 6 months were evaluated 
• Males (n=74); aged 41 to 87 years) 
• females (n=76); aged 33 to 86 years, were evaluated 
Periodontal Variables:  
• PI and GO index 
Drug variables: 
• Dosage – 5mg/day 
• Duration – minimum 6 months 
Average Plaque index: 
• Males : 45%, Females: 32% 
Exhibiting mild hyperplasia: 
• Males: n=3/74 (4.1%) 
• Females: n= 2/76 (2.6%) 
Conclusion: 
• Overall prevalence of AIGO was 3.3%. 
• 5 mg/day of Amlodipine did not induce GO 







Investigated whether the choice of 
CCB used in  conjunction with 
Cyclosporin- A, affected the 
prevalence of GO 
135 renal transplant recipients on cyclosporin A in combination with either nifedipine 
(n=89) or amlodipine (n=46) for at least 12 months were evaluated in two centers: 
Manchester and Belfast 
• Cyclosporine-A + Nifedipine : Males (70) and females (19); age (41.4±13.4 
years) 
• Cyclosporine-A + Amlodipine :  Males (30) and females (16); age (43.6±12.9 
years)  
Periodontal Variables: 
- GO index 
Drug Variables: 
Mean dosage (mg/day) of cyclosporine-A in  Nifedipine group> to Amlodipine group 
Duration : at least 12  months 
• Amlodipine group : 72% of the subjects had GO 
• Nifedipine group : 53% of the subjects had GO 
• Prevalence of overgrowth in young subjects (±70%) was 
more in both groups 
• In older subjects the prevalence of overgrowth was less in 
nifedipine treated (40%) than amlodipine treated (72%) 
subjects.   
Conclusion:  
• GO in renal transplant recipients maintained on 
cyclosporin A + nifedipine < than with cyclosporin A + 
amlodipine. 
• Nifedipine was a better drug of choice in older transplant 
recipients than amlodipine to reduce the incidence of 
overgrowth 
 
Akimoto  et al. 
2003(11) 
Japan Cross-sectional  
study 
Determined if  
amlodipine caused GO 
 
Evaluated 1,195 patients on CCB’s 
• Amlodipine (n = 121), Barnidipine (n =25), Benidipine (n = 28), Cinnarizine (n= 
46), Diltiazem (n= 168), Flunarizine (n= 32), Manidipine (n= 93), Nicardipine 
(n= 210), Nifedipine (n= 272), Nilvadipine (n= 58), Nisoldipine (n= 84), 
Nitrendipine (n= 25) , Veramapil (n= 33) for >3 months 
• Clinical diagnosis of DIGO was verified by disappearance or decreased severity 
of GO after withdrawal of the causative drug 
Periodontal variables -not reported 
Drug Variables- Duration of amlodipine therapy >3 months 
• Withdrawal of amlodipine for 2 months caused reduction 
in size of overgrowth 
• Incidence of GO 
Nifedipine (8.5%), Diltiazem (4.8%), Amlodipine (1.7%), 




Amlodipine caused GO 
Table 1: Characteristics of the original research studies included in systematic review.
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Meisel P  et al., 2005 
(12) 
Germany Cross sectional 
study 
Investigated the association 
between the intake of calcium 
antagonists and periodontitis in a 
population-based analysis 
including the most important risk 
factors of periodontitis 
4290 subjects aged 20– 80 years, were evaluated to note the periodontal risk factors 
and to identify participants on CCB’s 




PD, CAL,  Smoking status was also recorded 
 
• 15.9% of participants used amlodipine 
• Subjects treated with CCB’s had significantly deeper 
gingival pockets than controls known risk factors of 
periodontitis 
• The risk of GO was aggravated in smokers 
Conclusions: 
• Treatment with CCB’s leads to GO without aggravation of 
periodontal disease.  
• Interaction with smoking indicated the multifactorial 
background of the undesired effect of these drugs 
Naik ZA  et al., 
2011(13) 
India Case Control 
study 
Determined the association 
between GO and the use of 
different CCB’s and also assessed 
the status of gingiva in them as 
well as the relationship between 
the dosage and duration of intake 
of CCB on GO 
Total of 60 were divided into : 
• Cases : (n=30) on CCB’s ( age:36-68 years; mean of 50.53±9 years) 
• Controls (n=30) not on any drugs known to cause GO (age: 32-63 years ; mean 
age : 49.37±8 years 
Periodontal Variables: 
• Oral hygiene index, GI, PI, GO index 
Drug variables:  
• Duration of therapy with CCB’s ≥ 6 months 
 
• 28 subjects were on amlodipine therapy for > 6 months 
• Among cases 25(83%) females and 5(17%) males had GO 
Dosage of amlodipine: 
• < 5mg/day : n=24 
• > 5mg/day: n= 4 
Duration of therapy: 
• < 5 years : n=20 
• > 5 years: n=10 
Conclusions: 
• Slightest of plaque triggered the gingival response to 
CCB’s 
• GO provided new niches for growth of microorganisms, 
resulting in tooth loss.  
• Good oral hygiene is imperative in patients on CCB’s. 
Karnik R  et al., 
2012(14) 
India  Cross sectional Determined the prevalence of 
AIGO among 
elderly subjects attending an 
Indian teaching hospital and also 
the association of AIGO with 
demographic 
factors, drug variables, oral 
hygiene status and gingival 
inflammation 
157 dentate patients aged ≥ 60 years on amlodipine for at least 3 months were 
evaluated 




PI, GI, GO index 
Drug variables:  
Drug dosage: 
• 2.5 mg/day: n=21 subjects (13.4%)  
• 5 mg/day: n=77 subjects (49%)  
• 10 mg/day: n=59 subjects (37.6%)  
Development of GO: 
• Total 8 patients (5.09%) (males=4 and females =4)  
Dosage: 
• 10 mg/day: 5/8 subjects (62.5%) 5 mg/day:  3/8 subjects 
(37.5%) 
Duration:  
• 4-6 month : n=1 
• 12- to 24-month : n=2 
•  > 24-month : n=5 
• No statistically significant relation was observed between 
age, gender, drug dosage and duration of drug intake and 
prevalence of GO 
 
Duration of drug therapy (3-4, 4-6, 6-12, 12-24 and >24 months) Conclusions: 
• GO prevalence was significantly correlated with plaque 
and gingival index scores 
• Prevalence of AIGO in the sample of elderly Indians was 
higher than previously reported.  




India Case Control 
study 
• Studied the distribution of 
B-cell 
lymphoma/leukemia-2 
Gene (Bcl-2) in healthy and 
AIGO tissues 
• Compared and correlated 
Bcl-2 expression in gingival 
samples from subjects on 
amlodipine therapy to that 
in healthy controls  
Total of 25 subjects divided into 2 groups: 
• Cases ( n=15) [hypertensives on amlodipine for minimum of 6 months;   10 
females and 5 males; age group 32-67 years) 
• Controls (n=10) [systemically healthy;  5 males, and 5 females; age group 26-56 
years] 
Periodontal variables:  
• PI, GI,  Degree of GO 
• Expression of Bcl2 gene in the tissue samples Bcl2 expression in GO and 
healthy gingival samples 
Drug Variables: 
• Dosage – not mentioned 
• Duration of therapy (6 months to > 5 years) 
Among cases: 
Score I : n=9 
Score II : n=4 
Score III : n=2 
Correlation between the duration of therapy and GO: 
• 6 months to 2 years (n=7) - 100% of the showed an 
overgrowth score of I  
• 2-4 year period (n=6)- 80% of the cases showed a GO 
score of II 
• >5 year (n=2) - 100% of cases showed GO index score of 
III 
Bcl-2 staining: 
• Few control specimens (n=5) - weakly positive to Bcl-2 
antibody (distribution limited to the basal cell layers only) 
• Hyperplastic specimens (n=10) expressed Bcl-2 in both 
basal and Suprabasal layers.  
Conclusion: AIGO might involve inhibition of apoptosis, within 
the hyperplastic gingival epithelia  
Banthia R  et al., 2014 
(16) 
India Cross- sectional 
study 
Investigated and assessed 
the relationship between 
periodontal health and the onset 
and severity of GO in patients 
receiving amlodipine 
99 hypertensive patients on amlodipine for at least 6 months 
• both males and females 
• age range between 30 and 75 years 
Periodontal Variables: 
- PD, CAL, Calculus Index, Hyperplastic score 
- Patients divided into 3 groups according to HEL scoring as: Gingival healthy 
group (H-Group, score +2 to +1), Equivocal group (E-Group, score +0) and less 
healthy group (L Group, scoring −2 to -1) 
Drug Variables: 
Drug dosage (Amlodipine mg/day)-  
 
• A statistically significant difference in mean treatment 
duration, mean calculus scores, mean PPD, mean CAL 
and mean hyperplastic scores amongst H, E and L groups 
and between responders and non-responders 
 
Conclusion: Definite association between periodontal health 
and development and severity of AIGO 
Table 1 continue: Characteristics of the original research studies included in systematic review.
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• H group (n=31) (7.42±2.54 mg/day)  
• E group (n =31) (8.87±2.12mg/day) 
• L group (n=37) (8.11±2.11mg/day) 
Duration of treatment: 
• H group (n=31) (23.26±15.26 months) 
• E group (n =31) (35.39 ±20.72 months) 
• L group (n=37) (52.14±27.23 months) 
 
Tejnani A  et al., 2014 
(17) 
India Case control 
study 
Determined the incidence of 
AIGO in the rural 
population of Loni 
• 115 dental patients (aged 40 to 48 years) on amlodipine for more than 3 months 
were studied for DIGO 
• 100 patients on other hypertension drugs were taken as healthy controls  
• Clinical diagnosis of DIGO was verified by disappearance or decreased severity 
of GO after withdrawal of the drug 
Periodontal Variables: 
• PI, GI, GO index 
Drug Variables: 
• Drug dosage : not reported 
• Duration of Therapy: not reported 
• The prevalence rate of AIGO in the cases was 3.4% with 3 
males and 1 female subject 
• Severity of gingivitis and the GI level were greater in the 
amlodipine group as compared to the controls 
• Cases had statistically significant higher PI values than 
controls 
• The highest prevalence of gingival enlargement was in  
the fourth decade of life, with the incidence of overgrowth 
being higher in males compared to females 




Determined the prevalence and 
risk factors for GO in subjects on 
CCB’s 
133 patients on antihypertensives for a minimum of 3 months were examined for the 
presence of GO 
• Nifedipine : n=4; males=3, females=1, Mean age – 56.25 years 
• Amlodipine: n=102; males=59, females=43, Mean age – 55.8 years 
• Amlodipine + Metoprolol  n=4; males=2, females=2, Mean age – 58 years 
Periodontal Variables- 
- Gingival index (GI), plaque index, Calculus index and probing depth 
- Vertical and horizontal GO indices 
Drug variables: 
Median Dosage (mg/day): 
• Nifedipine : 10 
• Amlodipine: 5 
• Amlodipine + Metoprolol : 5+25 
Mean duration: 
• Nifedipine : 5.75 years 
• Amlodipine: 4.96 years 
• Amlodipine + Metoprolol: 6 years 
Frequency of GO: 
- Nifedipine : 75% (3/4) 
- Amlodipine : 31.4% (32/102) 
- Amlodipine + metoprolol : 25% (1/4)  
- Higher GI,PI, Calculus index and probing depths in 
patients on CCB’s 
- GI significantly correlated with GO 
Conclusion: 
- Patients on antihypertensives had poor oral hygiene and 
Gingival inflammation may promote development of 
DIGO 
- No correlation between dosage and duration of drug 
intake with GO 
 




Determined the prevalence of GO 
among renal transplant recipients 
and compared its occurrence in 
patients on tacrolimus with those 
on a combination of tacrolimus 
and amlodipine 
308 adult renal transplant patients divided into 2 groups: 
Group A (n=147) on tacrolimus (aged- 40.9 ± 13.1 years) 
Group B (n=161) on tacrolimus+ amlodipine (aged- 43.3 ± 13.8) years 
Periodontal Variables:  
• Simplified-oral hygiene index (OHI-S) 
• Vertical gingival overgrowth index 
Drug variables: 
• Drug dosage and duration of therapy -Not reported 
Among 308 patients: 
• Good oral hygiene: n=139 (45.1%) 
• Fair oral hygiene: n=121 (39.9%) 
• Poor oral hygiene: n=48 (15.6%) 
Group A (tacrolimus only) - good oral hygiene (61.9%) 
Group B (tacrolimus + amlodipine) fair oral hygiene (51.6%) 
Conclusion: GO in patients on both tacrolimus and amlodipine 
was statistically significantly associated with poor oral hygiene 
Jayanthi R  et al., 
2017(19) 
India Cross sectional Assessed the prevalence and 
severity of AIGO in hypertensive 
patients 
100 hypertensive patients on amlodipine or combination of amlodipine with other 
antihypertensive agents were evaluated 
Periodontal variables: 
• GO index 
Drug variables: 
• Drug dosage (mg/day) : 
2.5 (n=20), 5 (n=51), 7.5 (n=9) and 10 (n=20) 
• Duration of therapy: 1-3 years (n=44), 3-6 years (n= 20), 6-9 years (n= 18), >9 
years (n=18) 
 
Development of GO : 
• 61.8% of the patients on amlodipine 
Based on duration : 
• 1-3 years (n=34/44) (77.3%) 
• 3-6 years (n= 18/20) (90%) 
• 6-9 years (n= 14/18) (77.8%) 
• >9 years (n=10/18) (55.6 %) 
Based on dosage: 
• 2.5 (n=11/20) (55%) 
• 5 (n=41/51) (80.4%) 
• 7.5 (n=4/9) (44.4%) 
• 10 (n=18/20) (90%) 
68% incidence in females, 66% of patients > 50 years of age. 
Conclusions:  
No significant correlation was observed between age, gender, 
drug dosage and prevalence of GO 
Umeizudike KA  et al., 
2017 (20) 
Nigeria Cross sectional 
study 
Determined the association of 
CCBs with GO in hypertensive 
patients 
116 hypertensive patients,  mean age was 59.4 ± 12.6 years, 58 subjects on CCB’s  and 
58 not on CCB were evaluated 
Periodontal Variables: 
• PI, GI, GO index 
Drug Variables: 
• In the CCB group, 39 (67.2%) were on amlodipine and 19 
(32.8%) on nifedipine.  
• The mean duration of CCB use was 55.6 ± 53 months 
• DIGO was higher in CCB (36.2%) than that in non-CCB 
participants 
• Amlodipine users had higher DIGO (37.5%) than that of 
nifedipine users (21.1%) 
	
	
Dosage: mean dose: 8.5±4.2 mg/day 
Duration of therapy with CCB 55.6 ± 53 months (range: 6–276 months). 
Other variables: Tobacco, smoking, Herbal agents 
Conclusion: 
Risk of GO  was three times in CCB than that of non-CCB users 
and twice higher in amlodipine than nifedipine users in Nigeria. 
Table 1 continue-1: Characteristics of the original research studies included in systematic review.
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d. Drug variables
The mean dosage of amlodipine causing GO ranged 
from 2.5 to 10 mg/day. Two studies reported 2.5mg/
day dosage (14,19), five studies each reported 5mg/day 
(7,9,13,14,19) and 10mg/day (13,14,16,19,20) dosage 
therapy. One out of two studies reported GO with 2.5 
mg/day dosage (19), while all five studies with 5mg/day 
(7,9,13,14,19) and 10 mg/day (13,14,16,19,20) therapy 
reported GO. The duration of amlodipine therapy ran-
ged from 3 months to > 9 years. Four studies evaluated 
development of overgrowth with ≤ 6 months of therapy 
(9,11,14,15). However, majority of studies evaluated 
GO with > 6 months of therapy (7,10,13-16,19,20).
e. Main Outcomes
The risk factor for AIGO identified in majority of the 
studies was administration of amlodipine in patients 
with poor oral hygiene (7,13,14,16-18). A significant as-
sociation of AIGO was seen between PI and GI in these 
studies. Two studies reported presence of GO in amlodi-
pine patients but did not evaluate the levels of plaque and 
oral hygiene (11,20). The probing depth and CAL were 
associated with GO in two studies (12,16). Furthermore, 
smoking was suggested to promote GO independent of 
drug therapy in two studies (7,12). The dosage of the 
drug and duration were not significantly correlated with 
GO in three studies (7,14,19) while two studies repor-
ted probable association between the duration of therapy 
and AIGO (15,16). However, two studies, reported a re-
duction in size of GO following amlodipine withdrawal 
for two months (11,17). The lowest dose of drug causing 
GO was 2.5 mg/day in one study (19) while 10mg/day 
dosage resulted in rapid overgrowth (15). A minimum of 
3 months of therapy resulted in overgrowth in one study 
(11). Interestingly, two studies reported increased inci-
dence of GO in patients on amlodipine when compared 
to nifedipine (10,20).  Furthermore, a study in geriatric 
renal transplant patients suggested that amlodipine had a 
greater potential to cause GO in elderly than nifedipine 
and the latter should be considered in elderly renal trans-
plant patients (10). Two studies regarded smoking as an 
independent risk factor for AIGO (7,12).
The salient features of the studies and their outcomes 
have been summarized in table 1.
Arunachalam LT and Rao S in 2013 (15) studied the dis-
tribution of B-cell lymphoma/leukemia-2 Gene (Bcl-2) 
in healthy and AIGO tissues and also compared and 
correlated its expression in gingival samples from sub-
jects on amlodipine and healthy controls. Bcl-2 has been 
found to be associated with apoptosis which involves 
enhanced calcium influx or intracellular calcium re-lo-
calization and the calcium in the mitochondria. Bcl-2 
inhibits apoptosis by influencing the redistribution of 
intracellular calcium. It was found that few control spe-
cimens (n=5) were weakly positive to Bcl-2 antibody 
(distribution limited to the basal cell layers only) while 
hyperplastic specimens (n=10) expressed Bcl-2 in both 
basal and suprabasal layers. It was suggested that plausi-
bly apoptosis of gingival keratinocytes was inhibited in 
low calcium conditions as seen with amlodipine adminis-
tration, as sustained elevation of calcium was imperative 
to activate degradative enzymes such as calcium-depen-
dent protease and endonucleases responsible for DNA 
degradation. Besides, gingival keratinocytes grown un-
der low levels of calcium expressed Bcl-2, which inhi-
bited apoptosis. In contrast, keratinocytes grown under 
high levels of calcium expressed Bax, which induced 
apoptosis. Additionally this study also associated dura-
tion of therapy with gingival overgrowth as it reported 
that seven cases showed mild overgrowth within 6 mon-
ths to 2 years of therapy while six cases showed modera-
te GO within 2 to 4 years of therapy. Further, therapy for 
more than 5 years resulted in severe overgrowth in two 
cases. This could be related to prolonged exposure of 
tissues to amlodipine which enhanced the expression of 
Bcl2 and inhibited apoptosis of gingival keratinocytes.
Banthia R et al. in 2014 (16) investigated and assessed 
the relationship between periodontal health and onset 
and severity of GO in 99 patients on amlodipine. About 
68 patients taking 8.46±2.33 mg/day of amlodipine 
developed GO in < 5 years of therapy. Additionally a 
strong association was seen between periodontal health 
and GO.
Gopal S et al., 2015 conducted a cross-sectional study to 
determine the prevalence and risk factors for GO in sub-
jects on CCB’s. Of the 133 subjects evaluated 102 were 
on amlodipine. Among them about 32 subjects develo-
ped GO. It was suggested that patients on anti-hyperten-
sives had poor oral hygiene and gingival inflammation 
promoted development of DIGO. 
f. Quality of the included studies
STROBE-based quality analysis showed a high (sco-
re of 7) for two studies (7,12) and low for one study 
(score 3) (11) while all the other studies had an accep-
table scores of 5 (9,17) and  6 (10,13-16,18-20) (Table 
2). The most common shortcomings of all the studies 
were the lack of sample size calculation and failure to 
address the confounding factors. Furthermore, some did 
not report the dosage of amlodipine prescribed to all the 
patients. Duration of therapy and management were also 
inadequately reported. The overall quality of included 
studies for assessing risk factors for AIGO was fair. Ne-
vertheless, small sample sizes and the failure to report 
the dosage and duration of amlodipine therapy limits the 
application of these study outcomes. 
Discussion
For decades, amlodipine was regarded as a “safe drug” 
when compared to other CCB’s as it was associated with 
relatively few adverse reactions (21). This was mainly 
related to its longer duration of action requiring reduced 
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Jorgensen MG, 1997 (9) 1 1 0 1 1 0 1 0 5 
James JA et al., 2000 (10) 1 1 0 1 1 0 1 1 6 
Akimoto et al., 2003 (11) 0 1 0 0 1 0 1 0 3 
Meisel P et al., 2005 (12) 1 1 1 1 0 1 1 1 7 
Naik ZA et al., 2011 (13) 1 1 0 1 1 0 1 1 6 
Karnik R et al., 2012 (14) 1 1 0 1 1 0 1 1 6 
Arunachalam LT et al.,  
2015 (15) 
1 1 0 1 1 0 1 1 6 
Banthia R et al. 2014 (16) 1 1 0 1 1 0 1 1 6 
Tejnani et al. (2014) (17) 1 1 0 1 0 0 1 1 5 
Gopal S 2015 (7) 1 1 0 1 1 1 1 1 7 
Hassan F et al., 2015 (18) 1 1 0 1 0 1 1 1 6 
Jayanthi R et al., 2017 
(19) 
1 1 0 1 1 0 1 1 6 
Umeizudike KA et al., 
2017 (20) 
1 1 0 1 1 0 1 1 6 
 
Table 2: STROBE analysis for assessing quality of studies included in the systematic review.
dosage. Subsequently, there was an increase in its pres-
cription rate for hypertension and angina pectoris which 
increased its side effects including GO. The present sys-
tematic review explored the association of various plau-
sible risk factors for AIGO. Since most of this evidence 
has been reported in case control and cross sectional stu-
dies, this systematic review appraised their data to seek 
variables related to this purported rare occurrence.
In the past the prevalence of AIGO was 1.7% to 3.3% 
(21). Lately, the data suggests that there has been an in-
crease in the number of these cases (7). As this CCB is 
the most preferred drug for long term maintenance of 
hypertensive and angina patients, it is worth understan-
ding the various variables related to one of its major side 
effects, the GO. The pooled data in the present review 
revealed increased rate of GO (26.7%) among subjects 
on amlodipine. 
The mean age of occurrence of GO in the present review 
was about fourth to fifth decade of life which was similar 
to previous studies (7). Although, there is no sexual pre-
dilection for DIGO, the prevalence of CCB induced GO 
has been shown to be higher in males than females (7). 
This was seen in the present review as well.
Various drug variables like dosage, duration of therapy 
and concentration of drug in plasma and local fluids, like 
gingival crevicular fluid and saliva, play an important 
role in DIGO (6). According to Seymour, the dosage of 
drug is not a significant indicator of their effects on gin-
gival tissue, rather it was more appropriate to relate it to 
patient’s body weight. Furthermore, their concentration 
in body fluids was also considered important in this as-
pect (6). It has been postulated that a certain threshold 
concentration of the drug or its metabolite was essential 
to “activate” gingival fibroblasts (22).  However, increa-
sing the levels of drug above this threshold did not affect 
the severity of the lesion. Besides, a direct correlation 
was observed between the concentration of drug in local 
fluids and DIGO. Although the mean dose of amlodipine 
reported to cause GO in the above studies was ranged 
from 2.5 to 10 mg, most of the subjects were on 5mg/day 
therapy (Fig. 3a). This was contrary to a previous study 
which suggested that 5mg/day of amlodipine could not 
result in GO (9). Besides, 10 mg/ day resulted in a more 
severe form of GO in all the cases in one study (15). 
Therefore, it may be suggested that dosage of drug may 
have an impact on GO and cannot be ignored, specifica-
lly in responders. The duration of therapy with amlodi-
pine widely varied in this review with a minimum dura-
tion of six months in all the studies (Fig. 3b). One study 
reported a direct correlation between the degree of GO 
and duration of amlodipine therapy (15). Usually, the 
gingival manifestations of AIGO appear within the first 
three months of the drug administration (23) which was 
evident in one study in this review (11). Additionally, 
longer duration of therapy may increase the exposure of 
cells to amlodipine. This may enhance the expression of 
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Fig. 3: Total number of patients developing gingival overgrowth with various dosages and duration of the rapy with amlo-
dipine.
Bcl2, an antiapoptotic protein in cells in the presence of 
low calcium. Therefore, amlodipine could modify apop-
tosis of cells resulting in increased viability and growth 
(15). Subsequently, the cell cycle may be prolonged re-
sulting in hyperplasia. The variation in the development 
of GO among the subjects could also be related to their 
inherent genetic susceptibility. Lately, multidrug resis-
tant (MDR1) gene polymorphisms have been suggested 
to modify the inflammatory response to the drug (24). 
These subjects are classified as responders and special 
care should be taken while prescribing CCB’s in them. 
Besides, in two studies on renal transplant patients in 
the present review (10,18), amlodipine caused more GO. 
This may be related to altered pharmacokinetics of cy-
closporine A by amlodipine (25).
Poor plaque control was identified as a risk factor in 
almost all the studies. This concurs with previous stu-
dies that proposed that GO hampered routine oral hy-
giene measures (6). Additionally, plaque accumulation 
caused inflammatory enlargement which superimposed 
the DIGO. It has been shown that CCB’s like nifedipi-
ne concentrate more in the areas of inflammation whe-
re they produce direct effects on gingival keratinocytes 
(26). Besides, amlodipine may inhibit apoptosis of 
human gingival fibroblasts in the presence of pro-in-
flammatory cytokines like TNF-α in inflamed gingival 
tissues (27). It may increase their viability and number 
leading to hyperplasia. 
A combined non-surgical and surgical therapy with drug 
substitution is the most common treatment approach 
for DIGO. Although for AIGO non-surgical periodon-
tal therapy without drug replacement may improve the 
condition (28), surgical excision is more reliable as it 
eliminates the hyperplastic tissue and promotes plaque 
control. Furthermore, it improves the esthetics. It is es-
sential to substitute the drug to prevent any future recu-
rrences. The most common drug used for substitution is 
an ACE inhibitor. Additionally, genetic susceptibility of 
the individual has to be recognized for successful treat-
ment outcomes. Furthermore, it is imperative to educate 
the patients on maintenance of good oral hygiene throu-
gh both personal and professional care. They should be 
informed about this uncommon side effect at the initia-
tion of therapy to prevent complications. 
The limitations of this review include moderate accep-
tability of the studies included. Furthermore, there were 
variations in the study designs, sample sizes, inadequa-
te mea¬surement of drug and periodontal variables li-
miting the statistical analysis of the data. Longitudinal 
observational studies with exclusion of confounding va-
riables are desirable to evaluate the role of factors other 
than plaque in AIGO.
Conclusions
The results of this systematic review suggest that AIGO 
is no longer a rare occurrence. Plaque accumulation is 
an important risk factor for AIGO. Besides, inherent 
genetic susceptibility, drug dosage and duration of the-
rapy are other important risk factors. As amlodipine is 
the most preferred drug for long term maintenance of 
hypertension and angina, it is imperative to explain this 
adverse effect to the patients. They should be informed 
about the meticulous plaque control required to pre-
vent GO. Moreover, it is essential for the physician to 
recognize this condition and associated drug variables 
to effectively manage these cases. Combination therapy 
consisting of surgical and non-surgical periodontal the-
rapy with drug substitution is the most reliable method 
for management of AIGO.
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